Poseida therapeutics announces nomination of new car-t development candidate under collaboration with roche

Allogeneic, tscm-rich dual car-t for the treatment of hematologic malignancies, including multiple myeloma nomination triggers $15 million milestone payment to poseida, extending cash runway into early 2026 poseida cell therapy r&d day to take place on thursday, november 14 at 7 am pt / 10 am et san diego , oct. 17, 2024 /prnewswire/ -- poseida therapeutics, inc. (nasdaq: pstx), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and rare diseases, today announced the nomination of a new development candidate under its collaboration with roche. the nomination triggered a $15 million milestone payment from roche to poseida.
CAR Ratings Summary
CAR Quant Ranking